Ultragenyx Pharmaceutical Inc. shares rose in the extended session Thursday after the biotech company reported positive results in a drug study meant to treat a rare metabolic disorder. Ultragenyx shares rose 3% to $51 after hours. In a late-stage clinical trial, the company said its recombinant human beta-glucuronidase treatment reduced the loss of certain complex carbohydrates needed to maintain tissue health in patients with Mucopolysaccharidosis 7.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.